Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing

Annals of Pharmacotherapy

Volumn 38, Issue 9, 2004, Pages 1383-1388

  Gosselin, Robert C ^a   King, Jeffrey H ^a   Janatpour, Kim A ^a   Dager, William E ^a   Larkin, Edward C ^a   Owings, John T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activated partial thromboplastin time; Anticoagulation; Direct thrombin inhibitors

Indexed keywords

ACTIN; ARGATROBAN; ELLAGIC ACID; HIRULOG; LEPIRUDIN; REAGENT; THROMBIN INHIBITOR;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; DRUG BLOOD LEVEL; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS;

BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; FIBRINOLYTIC AGENTS; HIRUDINS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; THROMBIN;

EID: 4143113354     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D565     Document Type: Article

References (10)

1. Dager WE, White RH. Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin Pharmacother 2003;4:919-40.
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55.
3. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
4. Cho L, Kottke-Marchant K, Lincoff AM, Roffi M, Reginelli JP, Kaldus T, et al. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. Am J Cardiol 2003;91:1110-3.
5. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69:157-63.
6. Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002;28:361-8.
7. Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, et al. Ecarin clotting time but not aPTT correlates with PEO-hirudin plasma activity. J Thromb Thrombolysis 2001;12:165-9.
8. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993;70:286-8.
9. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9.
10. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.